AU
UK
CA
NZ
IND
US
Tourmaline Bio, Inc. (NASDAQ: TRML) operates as a clinical biotechnology company focused on developing therapies for immune and inflammatory diseases. Its lead asset, TOUR006, is a human anti-IL-6 monoclonal antibody designed to selectively bind interleukin-6, a proinflammatory cytokine implicated in various autoimmune and inflammatory …
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) has received an upgrade from Wall Street Zen, moving from a“Sell” ratingto a“Hold” ratingin its latest research note issued Wednesday. This change reflects a more neutral stance on the company’s near-term performance after previously negative sentiment.
CAMP4 Therapeutics Corporation (Nasdaq:CAMP), a clinical-stage biopharmaceutical company focused on developing regulatory RNA-targeting therapeutics, announced that it has entered into definitive securities purchase agreements with institutional and accredited investors for up to$100 million in gross proceedsthrough a private placement.
Insight Molecular Diagnostics, Inc. (Nasdaq:IMDX) announced that it has begun actively enrolling patients in its clinical trial to evaluate GraftAssureDx, its next-generation kitted transplant rejection test. Last week, the first patient was enrolled, marking a key milestone in the study. The official clinical trial …
Palisade Bio, Inc. (NASDAQ:PALI), a clinical-stage biopharmaceutical company developing therapies for autoimmune, inflammatory, and fibrotic diseases, announced that it has received a No Objection Letter (NOL) from Health Canada for its Clinical Trial Application. The approval allows the company to advance PALI-2108, a first-in-class …
AC Immune SA (NASDAQ: ACIU) has announced a strategic restructuring aimed at streamlining operations and concentrating resources on its highest-value programs. The plan includes a 30% workforce reduction and a narrowed focus on three clinical-stage active immunotherapy programs, along with small molecule programs targeting …
Zai Lab Limited (NASDAQ: ZLAB) announced that Hong Kong’s Department of Health has approved TIVDAK (tisotumab vedotin-tftv), its antibody-drug conjugate (ADC) therapy for adult patients with recurrent or metastatic cervical cancer who experienced disease progression during or after chemotherapy. This marks an important regulatory …
Kiniksa Pharmaceuticals International (NASDAQ: KNSA) received a rating downgrade from Wall Street Zen, shifting from a “strong-buy” to a “buy” recommendation in a recent research note issued on Saturday. This adjustment reflects a slightly more cautious stance from analysts, although sentiment toward the stock …
Cantor Fitzgerald reaffirmed its “neutral” rating on shares of Molina Healthcare (NYSE: MOH - Get Free Report) in a research note issued Tuesday, according to Benzinga. The firm set a target price of USD 210.00, suggesting potential upside of just over 20% from the …
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has entered a strategic partnership with InvestorHub, a direct-to-investor engagement software provider, as part of a broader effort to streamline communications with shareholders and the investment community. The agreement establishes an interactive investor hub designed to consolidate corporate …
Please wait processing your request...